Business
AXIM® Biotechnologies Launches New Website and Management Presentation To Outline Strategic Business Initiatives
AXIM® Biotechnologies Launches New Website and Management Presentation To Outline Strategic Business Initiatives.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\nNEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the launch of a new corporate website and release of its most recent management presentation, which outlines the Company’s strategic initiatives including the prioritization of its clinical development program by probability of success and fiscal considerations. The website can be found at AXIMBiotech.com and the presentation can be downloaded there.\n “One of my first enterprises as CEO of the company was to implement a strategic business plan for the short and midterm that focused our clinical development research on programs with the best chance of success with lesser fiscal obligations,” said AXIM® Biotech CEO, John W. Huemoeller II.  “We felt that a redesign of our website and management presentation was an important step in making AXIM’s direction clear and making that information available to our valued shareholders. I encourage our shareholders to review the newly released website and presentation to gain an understanding of where we are headed in our clinical development program and the factors that led us to those decisions. We are striving to build a sustainable and successful company that revolutionizes cannabinoid pharmaceuticals and feel that this strategy is the best way to achieve that goal while building value for our shareholders.” AXIM Biotech will continue its research in cannabinoid pharmaceuticals utilizing its proprietary, controlled-release chewing gum delivery system, focusing on the following programs in the short and midterm: MedChew™ with dronabinol, which targets treatment of chemotherapy-induced nausea and vomiting and is planned to undergo a bioequivalence study as compared to FDA-approved Marinol®MedChew™ RL, which is planned to undergo clinical trials as a potential treatment for Restless Leg Syndrome (RLS)MedChew Rx, which will target treatment of pain and spasticity associate with Multiple Sclerosis and is planned to undergo human clinical trials for such treatmentCanChew™ Rx that aims to treat drug-induced psychosis These four clinical trial programs were selected due to their shortened timelines and o...